Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Bremelanotide PT 141 is a popular treatment option for hypoactive sexual desire disorder (HSDD) for premenopausal women because it is the first and only FDA-approved medication designed to treat this condition
However, that doesnt mean compounders can always create new delivery methods easily
Among those who have taken these drugs, about half (54%) including 53% of those with health insurance say it was either somewhat or very difficult to afford to pay for these drugs, including one in five (22%) who say it was very difficult, including a similar share of adults with health insurance (23%)
It is not yet approved for use in the UK
4 Causality assessmentnaranjo adverse drug reaction probability scale A Naranjo score of 7 places this reaction in the probable category ( Table 2 )
